X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with ALEMBIC PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs ALEMBIC PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA ALEMBIC PHARMA GSK PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 62.3 30.6 203.8% View Chart
P/BV x 10.0 7.0 143.5% View Chart
Dividend Yield % 1.3 0.7 187.3%  

Financials

 GSK PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
ALEMBIC PHARMA
Mar-16
GSK PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs3,838792 484.8%   
Low Rs2,637443 595.3%   
Sales per share (Unadj.) Rs354.2167.0 212.1%  
Earnings per share (Unadj.) Rs39.838.2 104.2%  
Cash flow per share (Unadj.) Rs42.942.0 102.1%  
Dividends per share (Unadj.) Rs30.004.00 750.0%  
Dividend yield (eoy) %0.90.6 143.0%  
Book value per share (Unadj.) Rs236.984.9 279.1%  
Shares outstanding (eoy) m84.70188.52 44.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.13.7 247.3%   
Avg P/E ratio x81.416.2 503.3%  
P/CF ratio (eoy) x75.514.7 513.7%  
Price / Book Value ratio x13.77.3 187.9%  
Dividend payout %75.410.5 719.8%   
Avg Mkt Cap Rs m274,216116,383 235.6%   
No. of employees `0004.7NA-   
Total wages/salary Rs m4,8304,214 114.6%   
Avg. sales/employee Rs Th6,387.0NM-  
Avg. wages/employee Rs Th1,028.3NM-  
Avg. net profit/employee Rs Th717.1NM-  
INCOME DATA
Net Sales Rs m30,00031,487 95.3%  
Other income Rs m72855 1,321.6%   
Total revenues Rs m30,72831,542 97.4%   
Gross profit Rs m4,19010,060 41.6%  
Depreciation Rs m263722 36.4%   
Interest Rs m037 0.0%   
Profit before tax Rs m4,6559,356 49.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,7442,160 80.7%   
Profit after tax Rs m3,3687,194 46.8%  
Gross profit margin %14.031.9 43.7%  
Effective tax rate %37.523.1 162.3%   
Net profit margin %11.222.8 49.1%  
BALANCE SHEET DATA
Current assets Rs m16,74215,066 111.1%   
Current liabilities Rs m7,2027,674 93.8%   
Net working cap to sales %31.823.5 135.5%  
Current ratio x2.32.0 118.4%  
Inventory Days Days5267 77.4%  
Debtors Days Days2141 51.1%  
Net fixed assets Rs m8,6358,237 104.8%   
Share capital Rs m847377 224.7%   
"Free" reserves Rs m19,22215,416 124.7%   
Net worth Rs m20,06916,005 125.4%   
Long term debt Rs m100-   
Total assets Rs m30,03824,594 122.1%  
Interest coverage xNM255.2-  
Debt to equity ratio x00-  
Sales to assets ratio x1.01.3 78.0%   
Return on assets %11.229.4 38.1%  
Return on equity %16.844.9 37.3%  
Return on capital %25.558.7 43.4%  
Exports to sales %055.7 0.0%   
Imports to sales %010.4 0.0%   
Exports (fob) Rs mNA17,551 0.0%   
Imports (cif) Rs mNA3,283 0.0%   
Fx inflow Rs m52817,811 3.0%   
Fx outflow Rs m7,1935,318 135.3%   
Net fx Rs m-6,66512,493 -53.4%   
CASH FLOW
From Operations Rs m2,3609,304 25.4%  
From Investments Rs m3,008-3,105 -96.9%  
From Financial Activity Rs m-5,108-1,959 260.7%  
Net Cashflow Rs m2604,240 6.1%  

Share Holding

Indian Promoters % 0.0 74.1 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 2.9 351.7%  
FIIs % 23.8 9.1 261.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 13.9 110.8%  
Shareholders   102,036 49,328 206.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  VENUS REMEDIES  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Firm US Markets; Sun Pharma, Software Stocks & Other Top Cues to Sway the Markets Today(Pre-Open)

Indian share markets finished the previous trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Blueprint for Sensex 100,000(The 5 Minute Wrapup)

Feb 20, 2018

Investing in stocks is not about index gazing. There are 3-Ms that could help pick the right stocks.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

A New Quest for the Stock Market's MOST Profitable Ideas...(Smart Contrarian)

Feb 23, 2018

If you want to receive the best ideas in the Indian stick markets...you need to heed this important announcement.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Feb 26, 2018 09:09 AM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS